NCT02161341

Brief Summary

The ocular surface is the first line of defence of the eye, it is therefore where external threats are sensed, and potential insults neutralised. Over the course of evolution, various microbes, especially bacteriae, have come to colonise the ocular surface as commensals. The commensals have a role to maintain the homeostasis of the ocular surface. 1 The innate immunity of the ocular surface is very active, and consists of active mechanisms to suppress inflammation 2. For example, there exist macrophages, dendritic cells, suppressor cells, regulatory cells, B cells, IgA, lysozyme, anti-microbial peptides and barriers against external agents. The normal commensals of the ocular surface maintain a basal level of activation of innate defence by stimulating the pattern recognition receptors on ocular surface epithelial cells. This normal composition of microbes is important since inflammation and infection will result if there is introduction of a pathogenic strain that overcomes the flora, or if a dominant strain secretes excessively immunogenic products, such as the exotoxin A of Staphylococcus which triggers marginal keratitis, a form of type IV hypersensitivity. The flora load of microbiome could also influence tear function as a higher flora load was found to be associated with increased mucin degradation 3 and reduced globet cell densitiy 4. Previous studies \[I'm not sure which studies these are\] at SERI/SNEC also point to the importance of microbes. For example, in dry eye patients, there is increased lysophospholipids in the tear, and this may contribute to inflammatory mediators such as arachidonic acid and other metabolites. The lysophospholipids are formed by phospholipase A2 reactions, and the latter may be microbial in origin. Since dry eye is a known inflammatory disease of the ocular surface, this is one way that microbes can contribute to the pathology.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

June 9, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 11, 2014

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

October 31, 2018

Status Verified

October 1, 2018

Enrollment Period

4.3 years

First QC Date

June 9, 2014

Last Update Submit

October 29, 2018

Conditions

Keywords

Bacterial microbiomeGene expression

Outcome Measures

Primary Outcomes (1)

  • bacterial microbiome

    Determine the composition of the bacterial microbiome of the human ocular surface in normal volunteers and dry eye patients

    1 day

Secondary Outcomes (2)

  • Gene expression

    1 day

  • Clinical characteristic

    1 day

Eligibility Criteria

Age21 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Dry eye patients and healthy normal volunteers

You may qualify if:

  • Subjects must be 21 years or older
  • Willing to perform all the eye examinations in this study

You may not qualify if:

  • Known history of thyroid disorders (diagnosed by physician).
  • Known history of Sjogren syndrome or rheumatoid arthritis (diagnosed by physician).
  • No ocular surgery within the last 3 months and LASIK within 1 year.
  • Ocular surface diseases such as pterygium, or obvious lid/orbital disease with lagophthalmos.
  • Any other specified reason as determined by clinical investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Singapore Eye Research Institute

Singapore, 168751, Singapore

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Microbiome swab will be collected from the inferior fornix of the lower eyelids to determine composition of the bacterial microbiome of the human ocular surface in normal volunteers and dry eye patients

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinician-Scientist, Senior Consultant

Study Record Dates

First Submitted

June 9, 2014

First Posted

June 11, 2014

Study Start

June 1, 2014

Primary Completion

October 1, 2018

Study Completion

October 1, 2018

Last Updated

October 31, 2018

Record last verified: 2018-10

Locations